Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
BOSTON, May 07, 2018 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Thursday, May 10, 2018 at 8:00 a.m. ET to discuss its first quarter 2018 financial results and provide a business update.
To participate in the conference call, please dial (888) 584-2172, (774) 264-7578 (international) and refer to conference ID: 4076397. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Amy Sullivan
SVP, Corporate Affairs
T: 617-466-3519
[email protected]
